Vanguard Capital Wealth Advisors Gilead Sciences, Inc. Transaction History

Vanguard Capital Wealth Advisors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 01, 2021	SELL	$67.69 - $73.03 $224,256 - $241,948	-3,313 Closed	0 $0
Q2 2021 Jul 28, 2021	SELL	$63.47 - $69.35 $353,083 - $385,794	-5,563 Reduced 62.67%	3,313 $228,000
Q1 2021 Apr 12, 2021	BUY	$60.0 - $68.46 $532,560 - $607,650	8,876 New	8,876 $573,000
Q4 2020 Jan 25, 2021	SELL	$56.65 - $64.55 $218,782 - $249,292	-3,862 Closed	0 $0
Q2 2020 Aug 05, 2020	SELL	$72.34 - $84.0 $121,531 - $141,120	-1,680 Reduced 30.31%	3,862 $297,000
Q4 2019 Jan 28, 2020	SELL	$61.62 - $67.78 $23,353 - $25,688	-379 Reduced 6.4%	5,542 $360,000
Q3 2019 Oct 18, 2019	BUY	$62.51 - $69.0 $370,121 - $408,549	5,921 New	5,921 $375,000

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Vanguard Capital Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Vanguard Capital Wealth Advisors with notifications on news.